Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9PIK3CAPIK3CBPIK3CD
The experimentally established mechanism targets of Fimepinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 7/20 | 1.00 |
| ▸ | HDAC10 known ✓ | Q969S8 | 7/20 | 1.00 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 7/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 6/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 6/20 | 1.00 |
| ▸ | HDAC4 known ✓ | P56524 | 5/20 | 1.00 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 5/20 | 1.00 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 5/20 | 1.00 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 5/20 | 1.00 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 5/20 | 1.00 |
| ▸ | PIK3CA known ✓ | P42336 | 4/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 3/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 2/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 5/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 2/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fimepinostat SCHEMBL29353052 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29493089 | 1.00 | HDAC1 (1.00) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813120 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813054 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29666301 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813122 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813051 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL29666166 | 0.99 | HDAC1 (0.99) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813474 | 0.97 | HDAC1 (0.94) | HDAC1HDAC2HDAC10HDAC11HDAC6 | |
| Fimepinostat SCHEMBL12813327 | 0.97 | HDAC1 (0.94) | HDAC1HDAC2HDAC10HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-3664789-B1 | METHODS FOR TREATING DISEASES AND NERVE INJURY | CHILDRENS HOSPITAL MED CT (US) | 2023-11-22 | — | — | EP | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | claimed |
| US-20190070166-A1 | Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease | POSTREL RICHARD (US) | 2019-03-07 | — | — | US | claimed |
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048193-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2017-03-23 | — | — | WO | claimed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025217247-A1 | TETHERED SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2012135571-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | HDAC1 135/4885HDAC2 286/4885HDAC10 591/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | HDAC1 3058/4885HDAC2 4021/4885HDAC10 3469/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | HDAC1 1389/4885HDAC2 3398/4885HDAC10 1856/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | HDAC1 3846/4885HDAC2 4682/4885HDAC10 3260/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | HDAC1 10/4885HDAC2 27/4885HDAC10 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.